However, it remains unknown and speculative as to whether these PSMA‐PET staged cN1M0PC simply represents earlier detection of cN1M0PC with same biology disease had they been staged with conventional imaging at a later stage, and hence had a higher likelihood of ‘cure’ with earlier local therapy, or that they potentially reflect a more unique and potentially more favourable PSMA‐sensitive biology process compared to non‐PSMA expressing prostate cancer.19, 20. This evidence concerns the gene FOLH1 and prostate cancer.